147 related articles for article (PubMed ID: 34597459)
1. Pregnancy rates and outcomes in women with cystic fibrosis in the UK: comparisons with the general population before and after the introduction of disease-modifying treatment, 2003-17.
Esan OB; Schlüter DK; Phillips R; Cosgriff R; Paranjothy S; Williams D; Norman R; Carr SB; Duckers J; Taylor-Robinson D
BJOG; 2022 Apr; 129(5):743-751. PubMed ID: 34597459
[TBL] [Abstract][Full Text] [Related]
2. Pregnancy among cystic fibrosis women in the era of CFTR modulators.
Heltshe SL; Godfrey EM; Josephy T; Aitken ML; Taylor-Cousar JL
J Cyst Fibros; 2017 Nov; 16(6):687-694. PubMed ID: 28190780
[TBL] [Abstract][Full Text] [Related]
3. Rate of Uptake of Ivacaftor Use after U.S. Food and Drug Administration Approval among Patients Enrolled in the U.S. Cystic Fibrosis Foundation Patient Registry.
Sawicki GS; Dasenbrook E; Fink AK; Schechter MS
Ann Am Thorac Soc; 2015 Aug; 12(8):1146-52. PubMed ID: 26073026
[TBL] [Abstract][Full Text] [Related]
4. Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries.
Volkova N; Moy K; Evans J; Campbell D; Tian S; Simard C; Higgins M; Konstan MW; Sawicki GS; Elbert A; Charman SC; Marshall BC; Bilton D
J Cyst Fibros; 2020 Jan; 19(1):68-79. PubMed ID: 31196670
[TBL] [Abstract][Full Text] [Related]
5. Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data.
Keogh RH; Szczesniak R; Taylor-Robinson D; Bilton D
J Cyst Fibros; 2018 Mar; 17(2):218-227. PubMed ID: 29311001
[TBL] [Abstract][Full Text] [Related]
6. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal Trends in Real-World Outcomes after Initiation of Ivacaftor. A Cohort Study from the Cystic Fibrosis Registry of Ireland.
Kirwan L; Fletcher G; Harrington M; Jeleniewska P; Zhou S; Casserly B; Gallagher CG; Greally P; Gunaratnam C; Herzig M; Linnane B; McElvaney NG; McKone EF; McNally P; Mullane D; Ní Chróinín M; O'Mahony M; Plant BJ; Jackson AD
Ann Am Thorac Soc; 2019 Feb; 16(2):209-216. PubMed ID: 30427731
[TBL] [Abstract][Full Text] [Related]
8. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
[TBL] [Abstract][Full Text] [Related]
9. Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor.
Bessonova L; Volkova N; Higgins M; Bengtsson L; Tian S; Simard C; Konstan MW; Sawicki GS; Sewall A; Nyangoma S; Elbert A; Marshall BC; Bilton D
Thorax; 2018 Aug; 73(8):731-740. PubMed ID: 29748252
[TBL] [Abstract][Full Text] [Related]
10. Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data.
Sawicki GS; McKone EF; Pasta DJ; Millar SJ; Wagener JS; Johnson CA; Konstan MW
Am J Respir Crit Care Med; 2015 Oct; 192(7):836-42. PubMed ID: 26132840
[TBL] [Abstract][Full Text] [Related]
11. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.
Rowe SM; Heltshe SL; Gonska T; Donaldson SH; Borowitz D; Gelfond D; Sagel SD; Khan U; Mayer-Hamblett N; Van Dalfsen JM; Joseloff E; Ramsey BW;
Am J Respir Crit Care Med; 2014 Jul; 190(2):175-84. PubMed ID: 24927234
[TBL] [Abstract][Full Text] [Related]
12. The outcome of pregnancy in women with cystic fibrosis: a UK population-based descriptive study.
Ashcroft A; Chapman SJ; Mackillop L
BJOG; 2020 Dec; 127(13):1696-1703. PubMed ID: 32683738
[TBL] [Abstract][Full Text] [Related]
13. The Effects of Ivacaftor on Bone Density and Microarchitecture in Children and Adults with Cystic Fibrosis.
Putman MS; Greenblatt LB; Bruce M; Joseph T; Lee H; Sawicki G; Uluer A; Sicilian L; Neuringer I; Gordon CM; Bouxsein ML; Finkelstein JS
J Clin Endocrinol Metab; 2021 Mar; 106(3):e1248-e1261. PubMed ID: 33258950
[TBL] [Abstract][Full Text] [Related]
14. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.
Heltshe SL; Mayer-Hamblett N; Burns JL; Khan U; Baines A; Ramsey BW; Rowe SM;
Clin Infect Dis; 2015 Mar; 60(5):703-12. PubMed ID: 25425629
[TBL] [Abstract][Full Text] [Related]
15. Real-World Outcomes Among Patients with Cystic Fibrosis Treated with Ivacaftor: 2012-2016 Experience.
Higgins M; Volkova N; Moy K; Marshall BC; Bilton D
Pulm Ther; 2020 Jun; 6(1):141-149. PubMed ID: 32304091
[TBL] [Abstract][Full Text] [Related]
16. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function.
Zhang S; Shrestha CL; Kopp BT
Sci Rep; 2018 Nov; 8(1):17066. PubMed ID: 30459435
[TBL] [Abstract][Full Text] [Related]
17. Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with Ivacaftor.
Borowitz D; Lubarsky B; Wilschanski M; Munck A; Gelfond D; Bodewes F; Schwarzenberg SJ
Dig Dis Sci; 2016 Jan; 61(1):198-207. PubMed ID: 26250833
[TBL] [Abstract][Full Text] [Related]
18. [Italian Cystic Fibrosis Registry (ICFR). Report 2017-2018].
Campagna G; Amato A; Majo F; Ferrari G; Quattrucci S; Padoan R; Floridia G; Salvatore D; Carnovale V; Puppo Fornaro G; Taruscio D; Salvatore M;
Epidemiol Prev; 2021; 45(3 Suppl 1):1-37. PubMed ID: 34132083
[TBL] [Abstract][Full Text] [Related]
19. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
20. Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis.
Whiting P; Al M; Burgers L; Westwood M; Ryder S; Hoogendoorn M; Armstrong N; Allen A; Severens H; Kleijnen J
Health Technol Assess; 2014 Mar; 18(18):1-106. PubMed ID: 24656117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
